oncolytic measles virus encoding thyroidal sodium iodide symporter
Biologicalexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2004 (NCT00408590)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Mesothelioma · Phase 1
- Multiple Myeloma · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1
- Nerve Sheath Neoplasms · Phase 1
- Neurofibromatosis 1 · Phase 1
- Ovarian Diseases · Phase 2
- Ovarian Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- oncolytic measles virus encoding thyroidal sodium iodide symporter
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02700230 | Phase 1 | Jun 1, 2017 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT02364713 | Phase 2 | Mar 1, 2015 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT02068794 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT01846091 | Phase 1 | Apr 1, 2013 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT01503177 | Phase 1 | Nov 1, 2011 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00450814 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2007 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00408590 | Phase 1 | Apr 1, 2004 | Mayo Clinic, National Cancer Institute (NCI) |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 7 | 7 | 2 | 2004 |
| National Cancer Institute (NCI) | Government | 7 | 0 | 2 | 2004 |
2 organizations
Page 1 / 1